Serum bone biomarkers including Ca (ionized Ca, where available), P, ALP, PTH, and 25(OH)D should be monitored regularly depending on CKD stage, underlying kidney disease, and presence and severity of MBD-related clinical and biochemical abnormalities, as suggested in Table 3. The gene discussed is PTH; the disease is chronic kidney disease.